Company news: GlaxoSmithKline, Human Genome Sciences, FDA

Share this article:
GlaxoSmithKline's $3.6-billion offer for Human Genome Sciences came with an added price. As first reported by the Washington Post, immediately upon the closing of its offer, several HGS board members resigned and were replaced with GSK executives. And immediately following the appointment of the GSK designees, "the HGS Board removed all of the executive officers of HGS," notes the tender offer statement GSK filed with the SEC.

The latest rates for the Medical Device User Fee Act are set -- the FDA published the new fee schedule Tuesday. The new rates will affect fiscal year 2013 and go into effect October 1. Fees will reboot October 1, 2013, upon the start of financial year 2014. MM&M reported in June that, unlike the pharmaceutical industry, which joined the talks over healthcare reform, the device industry cold-shouldered Capitol Hill. The excise tax is meant to raise $29 billion over a decade. The base fee for a pre-market application is $248,000 for financial year 2013, and business registration is $2,575.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.